By Fineline Cube 
Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon’s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.
Financial Terms and Partnership Structure
Under the deal, Creyon will receive a USD 13 million upfront payment, including cash and the purchase of Creyon equity. Additionally, Creyon is eligible to receive over USD 1 billion in development and commercialization milestone payments. Eli Lilly secures an exclusive license to lead candidates for each target and assumes full responsibility for clinical development and global commercialization moving forward.-Fineline Info & Tech